Equities research analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to report ($2.01) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Esperion Therapeutics’ earnings. The lowest EPS estimate is ($2.27) and the highest is ($1.53). Esperion Therapeutics posted earnings of ($1.86) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 8.1%. The firm is scheduled to report its next earnings report on Thursday, November 7th.
On average, analysts expect that Esperion Therapeutics will report full-year earnings of ($3.02) per share for the current financial year, with EPS estimates ranging from ($3.75) to ($2.14). For the next year, analysts expect that the business will report earnings of ($5.32) per share, with EPS estimates ranging from ($7.90) to ($3.55). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($2.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.86) by ($0.15). The business had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.05 million. During the same quarter in the prior year, the business posted ($1.71) EPS. The company’s revenue was up 9720.0% on a year-over-year basis.
Shares of NASDAQ:ESPR traded down $0.01 during trading on Monday, hitting $36.74. 339,651 shares of the company were exchanged, compared to its average volume of 537,681. The stock has a market cap of $979.24 million, a price-to-earnings ratio of -4.87 and a beta of 1.71. Esperion Therapeutics has a fifty-two week low of $33.13 and a fifty-two week high of $60.99. The firm has a fifty day moving average price of $37.88 and a two-hundred day moving average price of $44.31. The company has a current ratio of 5.65, a quick ratio of 5.65 and a debt-to-equity ratio of 0.01.
In related news, CEO Timothy M. Mayleben purchased 5,000 shares of the company’s stock in a transaction dated Friday, June 28th. The shares were purchased at an average cost of $46.00 per share, with a total value of $230,000.00. Following the transaction, the chief executive officer now directly owns 66,163 shares in the company, valued at approximately $3,043,498. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Timothy M. Mayleben acquired 2,500 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was purchased at an average price of $35.25 per share, with a total value of $88,125.00. Following the completion of the acquisition, the chief executive officer now owns 76,015 shares in the company, valued at $2,679,528.75. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 147,500 shares of company stock worth $5,521,825. 7.70% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of ESPR. State Board of Administration of Florida Retirement System lifted its holdings in shares of Esperion Therapeutics by 2.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 11,360 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 260 shares during the last quarter. Aperio Group LLC purchased a new position in shares of Esperion Therapeutics during the second quarter worth approximately $29,000. Russell Investments Group Ltd. purchased a new position in Esperion Therapeutics during the second quarter valued at approximately $32,000. Royal Bank of Canada increased its holdings in Esperion Therapeutics by 38.1% during the second quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 811 shares during the period. Finally, Swiss National Bank increased its holdings in Esperion Therapeutics by 2.0% during the second quarter. Swiss National Bank now owns 44,900 shares of the biopharmaceutical company’s stock valued at $2,089,000 after buying an additional 900 shares during the period.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.